|Table of Contents|

Efficacy and safety of piperoxiril,letrozole and fluvestrant in the treatment of advanced HR+/HER2- breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 05
Page:
838-842
Research Field:
Publishing date:

Info

Title:
Efficacy and safety of piperoxiril,letrozole and fluvestrant in the treatment of advanced HR+/HER2- breast cancer
Author(s):
CHEN Jingjing1; XI Zubin1; PEI Xiaohui2; LI Minglei1; BAI Shoulong1; YAO Licheng1
1.Hubei Common Steroid Drug Research Institute Co.,Ltd.,Hubei Wuhan 430000,China;2.Breast Center of Hubei Cancer Hospital,Hubei Wuhan 430000,China.
Keywords:
hormone receptors; human epidermal growth factor receptor 2; breast cancer; advanced; pipercillin; letrozole; fulvestrant
PACS:
R737.7
DOI:
10.3969/j.issn.1672-4992.2024.05.010
Abstract:
Objective:To investigate the clinical effect of combination of piperacillin,letrozole and fulvestrant on advanced hormone receptor positive/human epidermal growth factor receptor 2 negative(HR+/HER2 -) breast cancer.Methods:This study selected 120 patients with advanced HR+/HER2 - breast cancer who were treated in Hubei Cancer Hospital from January 2021 to January 2023,according to the treatment plan,patients were divided into an observation group(n=62) and a control group(n=58),the control group was treated with letrozole and fluvastatin,the observation group was treated with piperacillin,letrozole,and fluvastatin,the treatment efficacy,adverse reactions,and survival of the two groups were observed,and the differences in serum tumor markers and immune function between the two groups before and after treatment were analyzed.Results:The objective response rate(ORR) and disease control rate(DCR) of the observation group were 11.29% and 82.26%,respectively,which was significantly higher than those of the control group(P＜0.05).After treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 15-3(CA15-3),and carbohydrate antigen 125(CA125) in the observation group were(19.49±6.67)ng/mL,(11.54±3.34)U/mL,and(43.34±17.28)U/mL,respectively,which were significantly lower than those in the control group(P＜0.05).After treatment,the CD3+,CD4+,and CD4+/CD8+ levels in the observation group were(49.98±6.90)%,(31.02±7.00)%,and(1.18±0.39)%,respectively,which were higher than those in the control group(P＜0.05),while CD8+ levels were(26.38±3.35)%,which was lower than those in the control group(P＜0.05).There was no statistically significant difference in adverse reactions between the observation group and the control group(P＞0.05).The median progression free survival and overall survival in the observation group were 20 months(95%CI:18.87~21.14) and 25 months(95%CI:24.41~25.59),respectively,which was significantly higher than those in the control group(P＜0.05).Conclusion:Piperacillin,letrozole and fluvastatin have good clinical effect and safety in the treatment of advanced HR+/HER2- breast cancer,good safety,which can effectively regulate the level of tumor markers and improve the prognosis of patients.

References:

[1]GUERRERO J,LOUCERA C,M RAMIREZ-CALVO,et al.MamaPred:A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology［J］.Journal of Clinical Oncology,2021,39(15):558.
[2] TRUJILLO LG,GOMEZ ME,SOHN JH,et al.241P abemaciclib plus fulvestrant in participants with HR+/HER2- advanced breast cancer:A pooled analysis of the endocrine therapy nave(EN) participants in MONARCH 2［J］.Annals of Oncology,2021,32(8):464-465.
[3] RUEDESHEIM SM.Therapy of HR+/HER2-advanced breast cancer CDK4/6 inhibitors:Studies,everyday healthcare and guidelines［J］.Breast Care,2021,5(3):16-19.
[4] HAREL N,CHEEMA S,WILLIAMS D,et al.The IHC4+C score:an affordable and reproducible non-molecular decision-aid in hormone receptor-positive breast cancer.Does it still hold value for patients in 2020［J］.Asia-Pacific Journal of Clinical Oncology,2021,17(4):368-376.
[5] SHARMA M,MITTAPELLY N,BANALA VT.Amalgamated microneedle array bearing ribociclib-loaded transfersomes eradicates breast cancer via CD44 targeting［J］.Biomacromolecules,2022,23(3):661-675.
[6] 律慧敏,牛李敏,张梦玮,等.哌柏西利联合内分泌治疗对HR+/HER2-晚期乳腺癌患者的疗效观察［J］.中华医学杂志,2021,101(44):3625-3630. LYU HM,NIU LM,ZHANG MW,et al.Efficacy of piperacillin combined with endocrine therapy in patients with HR+/HER2- advanced breast cancer［J］.Journal of Chinese Medical,2021,101(44):3625-3630.
[7] CIRUELOS E,BOFILL F,MARTORELL AP,et al.73TiP SOLTI1710 PROMETEO II:Palbociclib in combination with letrozole in hormone receptor-positive(HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy(NAC)［J］.Annals of Oncology,2021,32(8):e333.
[8] LEUNG J,LEUNG H,WANG S,et al.Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive,HER-2-negative metastatic breast cancer:a network meta-analysis［J］.Expert Opinion on Drug Safety,2021,20(8):949-957.
[9] VIDAL GA,CARTER GC,GILLIGAN AM,et al.Development of a prognostic factor index among women with HR+/HER2- metastatic breast cancer in a community oncology setting［J］.Clinical Breast Cancer,2021,21(4):317-328.
[10] 郑方超,杜丰,刘昊琳,等.哌柏西利治疗HR+/HER2-乳腺癌新进展［J］.肿瘤防治研究,2022,49(7):703-708. ZHENG FC,DU F,LIU HL,et al.Recent progress of palbociclib in treatment of HR+/HER2- breast cancer［J］.Cancer Res Prev Treat,2022,49(7):703-708.
[11] NI J,KABRAJI S,XIE S,et al.Abstract 337:p16INK4A-deficiency predicts for response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases［J］.Cancer Research,2021,81(13):337.
[12] 姜丹丹,宋玉华.HR+/HER2+晚期乳腺癌药物治疗方案选择的研究进展［J］.中国肿瘤外科杂志,2021,13(6):546-551. JIANG DD,SONG YH.Progress of hormone receptor positive and human epidermal growth factor receptor 2 positive advanced breast cancer ［J］.Chin J Surg Oncol,2021,13(6):546-551.
[13] BOTTOSSO M,GIARRATANO T,BARBIERI C,et al.122P abemaciclib in HR+/HER2- metastatic breast cancer:A real-world experience［J］.Annals of Oncology,2021,32(8):S73-S74.
[14] 张文佳,孔佳禾,崔一民.哌柏西利治疗激素受体阳性/人表皮生长因子受体2阴性晚期/转移性乳腺癌的临床研究分析［J］.中国临床药理学杂志,2023,39(4):573-577. ZHANG WJ,KONG JH,CUI YM.Clinical trial analysis of palbociclib in the treatment of hormone receptor positive/human epidermal growth factor receptor 2 negative advanced/metastatic breast cancer［J］.Chin J Clin Pharmacol,2023,39(4):573-577.
[15] 韩颖,严颖,宛凤玲,等.ER阳性以及HER2阴性转移性乳腺癌患者应用哌柏西利联合内分泌治疗的真实世界研究［J］.肿瘤,2021,41(5):309-317. HAN Y,YAN Y,WAN FL,et al.Real-world study of patients with ER-positive and HER2-negative metastatic breast cancer receiving palbociclib combined with endocrine therapy［J］.Tumor,2021,41(5):309-317.
[16] GAO HF,LIN YY,ZHU T,et al.Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive,HER2-negative early breast cancer:A meta-analysis of randomized clinical trials［J］.The Breast,2021,59(8):165-175.
[17] TOLANEY SM,FALLOWFIELD L,KAUFMAN PA,et al.eMonarcHER:A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+,HER2+,node-positive,high-risk early breast cancer［J］.Journal of Clinical Oncology,2021,39(15):596.
[18] O MARTINEZ-SAEZ,TOLOSA P,TORRE A,et al.23P CDK4/6 inhibition and endocrine therapy(ET) in the HER2-enriched subtype(HER2-E) in hormone receptor-positive/HER2-negative(HR+/HER2-) advanced breast cancer(ABC):A retrospective analysis of real-world data［J］.Annals of Oncology,2021,32(8):30-34.
[19] 刘杰，刘琪，杜丽娟，等.DCE-MRI联合血清CEA、CA125水平检测评估进展期乳腺癌新辅助化疗疗效［J］.现代肿瘤医学，2021,29(16)：2821-2825. LIU J,LIU Q,DU LJ,et al.DCE-MRI combined with the detection of serum CEA and CA125 level in the evaluating the efficacy of neoadjuvant chemotherapy for advanced breast cancer［J］.Modern Oncology，2021,29(16)：2821-2825.
[20] DESOUZA K,YEO D,DIOSSY M,et al.Real-world outcomes from the systemic use of CDK 4/6 inhibitors(CDKIs) in the management of ER positive(+) HER2 negative(-) metastatic breast cancer(mBC)［J］.Journal of Clinical Oncology,2021,39(15):e13031.
[21] BELLO D,BERTUCCI A,ROUGE TDLM,et al.Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA-mutant advanced breast cancer:Data from the French early access program［J］.Journal of Clinical Oncology,2021,39(15):1064.

Memo

Memo:
国家重点研发计划(编号：2021YFC2100304)
Last Update: 2024-01-30